XML 59 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Co-Development Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended
Nov. 01, 2016
USD ($)
specie
Sep. 21, 2016
USD ($)
Feb. 03, 2015
USD ($)
Item
Mar. 31, 2018
USD ($)
Item
specie
Oct. 31, 2015
USD ($)
Mar. 31, 2018
USD ($)
Item
Mar. 31, 2017
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenues           $ 2,311,000 $ 941,000
Co Development Partnership Agreement [Member] | Canon U.S. Life Sciences Inc [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment     $ 2,000,000        
Additional consideration receivable upon achievement of certain development and regulatory milestones     6,500,000        
Aggregate consideration receivable     $ 8,500,000        
Proceeds received for achievement of milestone         $ 1,500,000    
Additional consideration receivable upon achievement of additional development and regulatory milestones       $ 5,000,000   $ 5,000,000  
Number of milestone payments | Item       2   2  
Additional consideration receivable upon achievement of development and regulatory milestones, payment one       $ 2,000,000   $ 2,000,000  
Additional consideration receivable upon achievement of development and regulatory milestones, payment two       $ 3,000,000   3,000,000  
Number of units | Item     1        
Revenues           0 300,000
Co Development Partnership Agreement [Member] | Allergan Sales [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment $ 2,000,000            
Aggregate consideration receivable $ 4,000,000            
Revenues           1,300,000 $ 38,000
Number of additional bacteria species added to existing product candidate | specie 1            
Co Development Partnership Agreement [Member] | CARB-X [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Number of additional bacteria species added to existing product candidate | specie       20      
Co Development Partnership Agreement [Member] | CARB-X [Member] | Maximum [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Aggregate consideration receivable       $ 2,000,000   $ 2,000,000  
Collaborative arrangement reimbursement amount       1,100,000      
Milestone payment       $ 900,000      
Private Placement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Proceeds from sale of shares in related party   $ 39,700,000          
Percentage of outstanding shares at date of sale   19.90%